THE CURRENT REIMBURSEMENT STRUCTURE FOR RADIOPHARMACEUTICALS IN THE MEDICARE HOSPITAL OUTPATIENT SETTING LIMITS PATIENT ACCESS TO DIAGNOSTICS AND STIFLES LIFE-SAVING INNOVATIONS.

CMS policies compromise Medicare beneficiary access. Today, not all Medicare Beneficiaries have access to molecular imaging to assist with the diagnosis of such diseases as Alzheimer’s, Parkinson’s, recurrent prostate cancer, or neuroendocrine tumors. Under the current inequitable payment methodology, many hospitals are unable to cover the cost of newer, targeted diagnostic radiopharmaceuticals.

Alternatively, sometimes less expensive tests patients are now receiving can result in inaccurate diagnoses or inappropriate treatment plans. Sick patients who seek accurate diagnosis or disease monitoring through advanced imaging with radiopharmaceuticals often travel long distances to access appropriate imaging services. Beneficiary’s possible health outcomes should not be impacted as the result of artificially low reimbursement.

“America’s patients deserve a health care system that supports and encourages access to innovative imaging techniques. That's why Congress should pass the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772).”

Patient Advocate, Josh Mailman in The Hill on October 18, 2019

The legislation resolves the payment inequity by affording payment of diagnostic radiopharmaceuticals, which meet a cost and date threshold. The payment methodology suggested in the legislation follows the existing payment methodology for other drugs.

This bill may also:

- Safeguard access to innovations that enhance patient care;
- Improve clinical outcomes;
- Incentivize research, development, and investment;
- Ensure Medicare patients receive medically necessary studies their physicians prescribe.

The proposed payment changes occur in a budget neutral manner.
Ensure Patient Access to Innovative Imaging Drugs

Cosponsor the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019

Current List of Organizations Supporting H.R. 3772

- Advanced Accelerator Applications/Novartis
- Alliance for Aging Research
- American Brain Coalition
- Avid/Eli Lilly & Co.
- Bayer HealthCare Pharmaceuticals
- Biogen
- Blue Earth Diagnostics
- Bracco Diagnostics
- BWXT Isotope Technologies (formerly Nordion)
- Cancer ABCs
- Cardinal Health
- Cerveau Technologies Inc.
- Council on Radionuclides and Radiopharmaceuticals (CORAR)
- Facing Our Risk of Cancer Empowered (FORCE)
- Curium
- Eckert & Ziegler Radiopharma, Inc
- FluoroPharma Medical
- GE Healthcare
- GO2 Foundation for Lung Cancer
- International Isotopes, Inc.
- Ionetix
- Jubilant Radiopharma
- Lantheus Medical Imaging
- Life Molecular Imaging (Formerly Piramal Imaging)
- Lymphoma Research Foundation
- Medical Imaging &Technology Alliance (MITA)
- Malecare
- Men’s Health Network
- National Alliance of State Prostate Cancer Coalitions
- NorCal CarciNET Community
- NorthStar Medical Technologies, LLC
- Northwest Medical Isotopes
- PharmaLogic
- Pharmalucence Inc.
- Progenics Pharmaceuticals, Inc.
- Prostate Cancer International
- SHINE Medical Technologies
- Siemens Healthineers
- Society of Nuclear Medicine & Molecular Imaging
- The Lymphoma Research Foundation
- UsToo
- ZERO- The End of Prostate Cancer
- Zionexa